• About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services
  • About us
    • Profile
    • Board of Directors
    • Research Leadership
  • Our Science
    • Strategy
    • Activities and Technologies
    • Publications
  • Pipeline
    • Pipeline
    • 68Ga-OncoFAP (Imaging)
    • 18F-OncoFAP (Imaging)
    • 177Lu-OncoFAP-23 (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • 68Ga-OncoACP3 (Imaging)
    • 18F-OncoACP3 (Imaging)
    • 177Lu-OncoACP3 (Therapy)
    • 225Ac-OncoACP3 (Therapy)
    • 68Ga-OncoCAIX (Imaging)
    • 177Lu-OncoCAIX (Therapy)
  • Press Release & Media
    • Press Releases
    • Events
    • Media Library
  • Work with us
    • Careers
    • Industrial Ph.D. Program
    • Partnering & Fee-For-Services

Philogen CEO/CSO, Dario Neri to give two lectures on September 1st

by mfantozzi | Aug 27, 2021 | 2021, Press Releases, Scientific

We are pleased to announce that Philogen co-founder and CEO/CSO, Prof. Dario Neri is giving two lectures on September 1st, 2021: At the virtual International Symposium on Medicinal Chemistry (EFMC-ISMC 2021) Prof. Neri is giving a presentation at 15:35 (CEST) with the...

Philochem, InterX and Scripps Research announce a Research Collaboration in the Field of DNA-Encoded Chemistry and Tumor Targeting

by last | Aug 23, 2021 | 2021, Press Releases

Philochem, a wholly owned subsidiary of Philogen S.p.A., InterX, Inc and Scripps Research announce a research collaboration to develop a best-in-class tumor targeting agent for metastatic prostate cancer. Philochem, InterX and Scripps Research...

Philochem, InterX and Scripps Research announce a Research Collaboration in the Field of DNA-Encoded Chemistry and Tumor Targeting

by last | Aug 23, 2021 | 2021, Press Releases, Scientific

Philochem, a wholly owned subsidiary of Philogen S.p.A., InterX, Inc and Scripps Research announce a research collaboration to develop a best-in-class tumor targeting agent for metastatic prostate cancer. Read More

Philogen to participate at the Goldman Sachs Eleventh Annual Biotech Symposium on September 7, 2021

by last | Aug 6, 2021 | 2021, Past Events

Philogen has been invited to participate at the Eleventh Annual Biotech Symposium organised by Goldman Sachs on September 7, 2021. The aim of the Symposium is to provide an opportunity for investors to get a broader perspective of the current opportunity set that...

Philogen to Participate at the KBC Life Sciences Conference on September 7-9, 2021

by last | Aug 6, 2021 | 2021, Past Events

Philogen has been invited to the Life Sciences Conference organised by KBC on September 7-9, 2021. The Conference provides an opportunity for investors to get a perspective of current opportunities and to meet CEO Dario Neri through a series of one-on-one meetings....

Philogen to participate at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 9-15

by last | Aug 6, 2021 | 2021, Past Events

Philogen has been invited to participate at the 19th Annual Global Healthcare Conference organised by Morgan Stanley on September 9-15, 2021. The conference format includes virtual fireside chats for (C-level only) and one-on-one meetings, providing management the...
« Older Entries
Next Entries »

Recent Posts

  • 2026 Swiss Chemical Society (SCS) Industrial Science Award for Samuele Cazzamalli, Head of Research at Philochem
  • Philochem to attend the Festival of Biologics 2025 in Basel on September 30-October 2, 2025
  • Philochem AG Announces Completion of Antitrust Clearance and Closing of the OncoACP3 Licensing Agreement with RayzeBio, a Bristol Myers Squibb Company, With a Potential Value of up to $1.35 Billion Plus Royalties
  • Philogen is pleased to invite you to a webinar with Prof. Dario Neri, taking place today, June 11, at 11:00 ET | 17:00 CET.
  • Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties.
Privacy Policy / Cookie Policy

Contacts

  • Follow

Philochem AG | Libernstrasse 3 | CH-8112 | Otelfingen – Switzerand |MWST-Nr/VAT-REG: CHE-113.181.443 | Registration Nr. CH-020.3.030.226-7 Ph. (+41) 43 544 88 00 | Fax (+41) 43 544 88 09| info@philochem.ch